Publications by authors named "Nadia M Issa"
Article Synopsis
- Ocrelizumab, a targeted monoclonal antibody for treating relapsing-remitting MS, significantly reduces relapse rates and disability compared to interferon beta 1a, while rituximab is often used off-label as an alternative.
- This study aimed to determine if rituximab's effectiveness is comparable (noninferior) to that of ocrelizumab in treating relapsing-remitting MS.
- The observational study included over 1600 patients from MS registries with matched baseline characteristics, focusing on annual relapse rates as the primary outcome measure.
Monozygotic twins discordant for narcolepsy type 1 and multiple sclerosis.
Neurol Neuroimmunol Neuroinflamm
August 2016